Treatment outcomes and associated factors among patients with rifampicin-resistant tuberculosis in Guangxi, 2020–2023

Background Rifampicin-resistant tuberculosis is a major challenge to tuberculosis control in Guangxi, China. This study aims to investigate the treatment status and influencing factors of rifampicin-resistant tuberculosis in the region from 2020 to 2023, and to provide evidence for precise prevention and control strategies. Methods Case information of tuberculosis patients in Guangxi was collected from the Tuberculosis Information Management System (a subsystem of the China Information System for Disease Control and Prevention). Treatment characteristics were described, chi-square test was used to analyze drug-resistant treatment status, and univariate and multivariate Logistic regression analyses were conducted to identify factors influencing treatment outcomes. Results A total of 1827 rifampicin-resistant tuberculosis patients were identified, and 1713 started treatment,with an overall treatment enrollment rate of 93.76% (trend χ 2 = 33.072, p < 0.05) showing a decreasing trend. Among the 1713 patients who initiated treatment, the treatment success proportion was 50.55% (866/1713). Males accounted for 79.97% of cases, and both genders had declining enrollment rates ( p < 0.05). The 40–59 age group made up 43.51%, and enrollment rates decreased in 20–39, 40–59, and ≥60 age groups (all p < 0.05). Enrollment rates across 14 cities ranged from 54.05% to 100%, with Liuzhou, Guigang, Hechi, and Laibin showing declines (all p < 0.05). Multivariate analysis identified male gender (OR = 1.48,95% CI:1.14–1.92), age≥60 years (OR = 4.11,95%CI:1.57–10.76), Zhuang ethnicity (OR = 1.75, 95% CI:1.4–2.18), other ethnicities (OR = 2.28,95% CI:1.33–3.92) and retreatment (OR = 1.57, 95% CI:1.28–1.92), as risk factors for unfavorable treatment outcome. Conclusion Guangxi’s rifampicin-resistant tuberculosis treatment enrollment rate is relatively high but declining. Strengthened efforts are needed to reverse this trend, Optimizing patient referral pathways, rationally distributing health resources and delivering targeted health education for high-risk groups are recommended to strengthen local RR-TB prevention and control.

Authors

Institutions

Publication Details

Journal
Frontiers in Public Health
Published
2026-11-16
DOI
https://doi.org/10.3389/fpubh.2026.1983542
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment outcomes and associated factors among patients with rifampicin-resistant tuberculosis in Guangxi, 2020–2023

Qingpeng Yang, 周崇兴, 崔哲哲, Jing Ye et al.
4 links
Frontiers in Public Health
Tuberculosis Research and Epidemiology
article

Treatment outcomes and associated factors among patients with rifampicin-resistant tuberculosis in Guangxi, 2020–2023

Qingpeng Yang, 周崇兴, 崔哲哲, Jing Ye, Huifang Qin, Yan Huang, Jianfeng Ou, Liwen Huang, Minying Huang
article en

Abstract

Background Rifampicin-resistant tuberculosis is a major challenge to tuberculosis control in Guangxi, China. This study aims to investigate the treatment status and influencing factors of rifampicin-resistant tuberculosis in the region from 2020 to 2023, and to provide evidence for precise prevention and control strategies. Methods Case information of tuberculosis patients in Guangxi was collected from the Tuberculosis Information Management System (a subsystem of the China Information System for Disease Control and Prevention). Treatment characteristics were described, chi-square test was used to analyze drug-resistant treatment status, and univariate and multivariate Logistic regression analyses were conducted to identify factors influencing treatment outcomes. Results A total of 1827 rifampicin-resistant tuberculosis patients were identified, and 1713 started treatment,with an overall treatment enrollment rate of 93.76% (trend χ 2 = 33.072, p < 0.05) showing a decreasing trend. Among the 1713 patients who initiated treatment, the treatment success proportion was 50.55% (866/1713). Males accounted for 79.97% of cases, and both genders had declining enrollment rates ( p < 0.05). The 40–59 age group made up 43.51%, and enrollment rates decreased in 20–39, 40–59, and ≥60 age groups (all p < 0.05). Enrollment rates across 14 cities ranged from 54.05% to 100%, with Liuzhou, Guigang, Hechi, and Laibin showing declines (all p < 0.05). Multivariate analysis identified male gender (OR = 1.48,95% CI:1.14–1.92), age≥60 years (OR = 4.11,95%CI:1.57–10.76), Zhuang ethnicity (OR = 1.75, 95% CI:1.4–2.18), other ethnicities (OR = 2.28,95% CI:1.33–3.92) and retreatment (OR = 1.57, 95% CI:1.28–1.92), as risk factors for unfavorable treatment outcome. Conclusion Guangxi’s rifampicin-resistant tuberculosis treatment enrollment rate is relatively high but declining. Strengthened efforts are needed to reverse this trend, Optimizing patient referral pathways, rationally distributing health resources and delivering targeted health education for high-risk groups are recommended to strengthen local RR-TB prevention and control.

Frontiers in Public HealthVol. 14
Guiyang Medical University (CN), Guangxi Center for Disease Prevention and Control (CN)
Good health and well-being
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon